Silymarin Attenuates Invasion and Migration through the Regulation of Epithelial-mesenchymal Transition in Huh7 Cells
![]() |
Kim, Do-Hoon
(Department of Clinical Laboratory Science, Dong-Eui University)
Park, So-Jeong (Department of Clinical Laboratory Science, Dong-Eui University) Lee, Seung-Yeon (Department of Clinical Laboratory Science, Dong-Eui University) Yoon, Hyun-Seo (Department of Dental Hygiene, Dong-Eui University) Park, Chung Mu (Department of Clinical Laboratory Science, Dong-Eui University) |
1 |
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. Silibinin inhibits |
2 |
Hsieh MJ, Lin CW, Yang SF, Chen MK, Chiou HL. Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF- |
3 | Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39: 305-318. DOI |
4 | Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298-302. DOI |
5 | Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497-2507. DOI |
6 | National Cancer Information Center (KR). Cancer statistics. Cancer incidence in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/S1T639C641/contents.do. |
7 | National Cancer Information Center (KR). Cancer statistics. Liver cancer incidence by histology group in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/program/S1T211C216/cancer/view.do?cancer_ seq=3317&menu_seq=3322. |
8 | Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454. DOI |
9 | Lee HS, Choi GH, Hwang HK, Kang CM, Choi JS, Lee WJ. The risk factors for extrahepatic recurrence after curative resection of hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg. 2010;14:227-234. |
10 | Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-235. DOI |
11 | Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:704-715. |
12 | Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. 1999. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999;112:4615-4625. |
13 | Huang C, Jacobson K, Schaller, MD. A role for jnk-paxillin signaling in cell migration. Cell Cycle. 2004;3:4-6. |
14 | Huang C, Jacobson K, Schaller MD. Map kinases and cell migration. J Cell Sci. 2004;117(Pt 20):4619-4628. DOI |
15 | Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, Lu KH. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 2007;28:977-987. |
16 | Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 2007; 354:165-171. DOI |
17 | Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196. DOI |
18 | Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-1437. DOI |
19 | Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890. DOI |
20 | van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5:1169-1179. DOI |
21 | Kim SM, Han JH, Park SM. The role of epithelial-mesenchymal transition in the gastroenterology. Kor J Gastroenterol. 2010; 56:69-77. DOI |
22 | Chen PN, Hsieh YS, Chiou HL Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156:141-150. DOI |
23 | Cufi S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol. 2013;60:360-368. DOI |
24 | Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29:447-463. DOI |
25 | Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011;4:1222-1232. DOI |
26 | Skottova N, Krecman V, Simanek V. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res. 1999;13:535-537. DOI |
![]() |